Cargando…
Urantide decreases hepatic steatosis in rats with experimental atherosclerosis via the MAPK/Erk/JNK pathway
Hepatic steatosis, an indicator of atherosclerosis (AS), is always accompanied by inflammatory responses and disturbances in lipid metabolism. The present study investigated the protective effect of urantide, a urotensin II (UII) receptor antagonist, on the liver of rats with AS with hepatic steatos...
Autores principales: | Cui, Haipeng, Lin, Yingxue, Xie, Lide, Zhao, Juan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
D.A. Spandidos
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7905324/ https://www.ncbi.nlm.nih.gov/pubmed/33604686 http://dx.doi.org/10.3892/mmr.2021.11923 |
Ejemplares similares
-
Urantide prevents CCl4-induced acute liver injury in rats by regulating the MAPK signalling pathway
por: Li, Ying, et al.
Publicado: (2021) -
The urotensin II receptor antagonist, urantide, protects against atherosclerosis in rats
por: ZHAO, JUAN, et al.
Publicado: (2013) -
The peptide compound urantide regulates collagen metabolism in atherosclerotic rat hearts and inhibits the JAK2/STAT3 pathway
por: Wang, Tu, et al.
Publicado: (2020) -
Urantide improves atherosclerosis by controlling C-reactive protein, monocyte chemotactic protein-1 and transforming growth factor-β expression in rats
por: ZHAO, JUAN, et al.
Publicado: (2014) -
Apple Polyphenols Decrease Atherosclerosis and Hepatic Steatosis in ApoE(−/−) Mice through the ROS/MAPK/NF-κB Pathway
por: Xu, Zhe-Rong, et al.
Publicado: (2015)